Resveratrol enhances the protective effects of calcium supplements on spinal cord injury-induced osteoporosis by targeting the SIRT1/FOXO3a pathway.

Spinal cord injury (SCI) often leads to osteoporosis due to factors like immobilization and hormonal imbalances. Calcium supplements are prescribed to help maintain bone health, but their efficacy may be limited. This study investigated whether resveratrol (RSV), a polyphenolic compound, could enhance the protective effects of calcium supplements on SCI-induced osteoporosis via the SIRT1/FOXO3a pathway, which regulates bone metabolism. Surgical cord transection induced SCI at the T9 vertebral level. An SCI mouse model was used with four groups: sham, SCI, SCI + 2% calcium, and SCI + calcium + RSV (20 mg/kg body weight). ‌‌‌‌‌‌‌‌‌‌‌‌‌‌‌‌‌‌Biomechanical testing, gene expression, and Western blots were performed. Resveratrol and calcium supplementation synergistically preserved bone mass, microarchitecture, strength, and fracture resistance compared to calcium alone after SCI. This was accompanied by upregulated osteoblast markers, downregulated osteoclast markers, and increased SIRT1/FOXO3a expression and activation. The results suggest resveratrol enhances calcium's bone-protective effects in SCI-induced osteoporosis by modulating the SIRT1/FOXO3a pathway and osteoblast/osteoclast activities. Combining resveratrol with calcium supplementation may be a promising therapeutic approach for managing SCI-induced osteoporosis.